Fractals: Life Science Conversations

What happens when human health, animal health, and entrepreneurial drug development intersect? In this episode of Fractals: Life Science Conversations , Bracken CEO Colin Miller is joined by Senior Partners Graham Lumsden, BVM&S, Dip. M., MRCVS, and Jonathan Larkin, PhD, to discuss osteoarthritis innovation, One Medicine, and the collaborative pathways that can move novel therapies forward. Togeth...

Pharmaceutical manufacturing still struggles with a fundamental challenge: turning complex science into reliable, scalable, real-world processes. Dr. Michael Choi has spent his career solving exactly that. As Founder of PCTS and a pioneer in tablet coating simulation, Michael has developed tools that bring clarity to one of the most complex—and often misunderstood—steps in drug production. In this...

What if maternal care was a proactive partner in your baby’s development, not just stepping in at a point of crisis? On this episode of Fractals , Cory Wyman, Director of Marketing at SimpliFed, joins Colin Miller to unpack how virtual lactation and baby-feeding support can reshape maternal health: clinically, emotionally, and economically. From the episode: Why baby feeding is often the first poi...

With more than two decades of experience spanning clinical practice, translational research, and global industry leadership, Bracken Senior Partner Dr. Deepak Behera has actively shaped how radiopharmaceuticals are developed, evaluated, and delivered to patients. As President and CEO of Adaptive Research and Senior Partner at Bracken, Deepak is an expert in connecting science, strategy, and real-w...

Mary Hardy, Chief Commercial Officer at SimpliFed, is helping reshape maternal health care with a virtual platform that supports families before birth and well beyond the baby’s first milestones. By combining lactation guidance, postpartum care, maternal mental health screening, and remote monitoring, SimpliFed is setting a new standard for holistic, accessible maternal care. In this episode of Fr...

What if a nasal spray could switch off acute social anxiety in minutes—without systemic side effects? Shawn Singh, CEO of Vistagen, joins Fractals to explain how pherines work: odorless intranasal molecules that tap the olfactory pathway to flip specific brain circuits on and off. Highlights from the episode: How pherines activate the nose → olfactory bulb → targeted brain regions in milliseconds....

With more than four decades of experience in oncology, cardiovascular imaging, ultrasound, and radioligand therapy, Dr. François Tranquart has helped shape the field of molecular imaging from both sides of the table—first as an academic physician and researcher, and later as an industry leader driving global clinical development. In this French-language episode of Fractals: Life Science Conversati...

What does it take to lead successful drug development—whether at a global pharma giant or a small biotech start-up? In this episode of SNiPs, Dr. David Krause joins Bracken CEO Dr. Colin Miller to reflect on three decades of experience spanning large organizations like GSK to fast-moving start-ups. From aligning clinical development with medical affairs to serving “many masters” in drug developmen...

With more than 30 years of experience spanning global pharma, emerging biotech, and the evolving field of personalized medicine, Bracken Senior Partner Dr. David Krause has helped shape the clinical and regulatory landscape across therapeutic areas—from vaccines and anti-infectives to neuropsychiatry and oncology. As a physician, former Chief Medical Officer, and trusted development advisor, David...

Can AI help radiologists see what humans can’t—and speed up drug development in the process? In this episode of SNiPs, Dr. Ben Larimer joins Bracken CEO Dr. Colin Miller to explore how artificial intelligence and machine learning are redefining what’s possible in molecular imaging. From interpreting complex PET scans to designing radiopharmaceuticals faster than ever, the future of diagnostics is...

As a scientist, innovator, and CEO of CytoSite BioPharma, Dr. Ben Larimer has reshaped how we think about imaging immune response in cancer. His work on Granzyme B PET imaging is unlocking unprecedented insights into whether—and where—immunotherapies are working inside the body. In this episode of Fractals , Ben joins host Colin Miller to discuss: The origins of Granzyme B imaging and what makes i...

With more than two decades of experience at the intersection of biostatistics and biomedical imaging, Bracken Senior Partner Dr. David Raunig has been a driving force in biomarker development, validation, and regulatory strategy. From leading FDA biomarker qualification review teams to co-inventing imaging advancements and setting industry-wide standards through QIBA, David has played a pivotal ro...

In drug development, the right biomarker can mean the difference between success and a missed opportunity.  In this episode of SNiPs, Bracken Senior Partner David Raunig, PhD explores how imaging biomarkers—like DXA and the fracture risk score—are being used in new ways to assess efficacy in clinical trials, especially for rare and complex diseases.  David breaks down the evolving landscape of FDA...

Scientist, entrepreneur, and investor—three small words to describe the way Hatch BioFund Managing Partner Dr. Lorenzo Pellegrini has devoted his career to translating the cutting-edge into impactful solutions. From founding six biotech companies to driving investments in industry-shaping firms like Elevation Pharmaceuticals and Anacor, Lorenzo has consistently championed the necessity of fusion b...

What does it take to balance bold innovation with prudent decision-making in biotech? Lorenzo Pellegrini, PhD, Managing Partner at Hatch BioFund, shares his perspective and experience on the strategic choices that define success—and survival—in the industry. From securing $20M to $200M in funding, to grappling with the complexities of portfolio diversification, Lorenzo unpacks the critical factors...

With career highlights including the launch of Ivermectin and NuvaRing, along with expertise spanning microbiome therapeutics, M&A, regulatory affairs, and clinical and non-clinical development, it’s no surprise that Bracken Senior Partner Dr. Graham Lumsden is striving to shift our approach to healthcare. Holding a doctorate in veterinary medicine, Graham takes an integrated approach that bridges...

In the biopharmaceutical industry, groundbreaking discoveries may start in the lab—but to reach the market, they require more than just great science. In this SNiP , life sciences veteran Dr. Graham Lumsden highlights an essential yet often overlooked step: identifying unmet medical needs before developing a solution. Drawing from decades of experience, Graham shares the value and necessity of a m...

One could describe Mary Costello as a world-class expert in international marketing, business initiatives, and leadership, with a background in patient advocacy, global marketing initiatives, and clinical trial solutions—and one would be correct. Her impressive career includes roles such as Head of Site and Investigator Network at Medable, Vice President of Clinic Development & Patient Advocacy at...

When launching a product or service, it all comes down to one essential question: what problem are you really trying to solve? In this SNiP , global marketing strategist and life science industry expert Mary Costello breaks down the essential steps to uncovering the root causes of a company’s marketing challenges. From the importance of understanding buyer behavior to the consequences of burning t...

With expertise in pharmacology, due diligence, strategic planning, peptide-based therapeutics, and beyond, it’s no wonder that Bracken co-founder and Managing Partner Dr. Jim Gilligan is also leading the way in therapeutic psychedelic drug development. With 35+ years of expertise, Jim’s cutting-edge work is reshaping our approach to mental health and chronic pain management. This integrated approa...

Imagine a world where therapeutic psychedelic drugs aren’t just visionary, but practical, scalable, and scientifically sound. That world is almost here. In this SNiP , Bracken Co-Founder and Managing Partner Jim Gilligan, PhD takes us behind the scenes of his groundbreaking advances in psilocybin treatment. Jim reveals how an integrated approach can turn bold ideas into commercial reality, with in...

Medical doctor, digital software and hardware programmer, and professional trainer—Bracken Senior Partner Paul Martinetti continues to defy a singular career path. Paul exemplifies an integrated approach: leading collaborative efforts to invent, build, and implement innovative solutions, such as an online photo-based acne severity consensus tool and a clinical study t-shirt, setting new industry s...

Start your project early, communicate with regulatory bodies often, and begin with the validation in mind—that’s Dr. Paul Martinetti’s starting advice for aspiring life scientists looking to bridge the gap between technology and healthcare. Tune into our latest SNiP , a special segment of Fractals Life Science Conversations , to hear more . Listen now, and stay tuned for the full episode of Fracta...

When you think about “people and platforms”, does “data analytics” come to mind? In this SNiP, our new special recurring segment of Fractals: Life Science Conversations , Bracken Senior Partner Ben Mitchell tells us exactly why data analytics, people, and platforms are the foundations for which life sciences thrives. Tune in to learn more about the importance of adopting an integrated approach to...

It's not just about the deal—it's about what happens next. In this episode of SNiPS, Bracken COO Dawn Flitcraft uncovers the surprising reactions and feelings of life science CEOs after their companies are acquired. Learn how having an integration leader and providing executive support can make all the difference. Listen now to hear how 95% of the time, these transitions lead to success.